Allergan acquires depression compound from Aptinyx

depression-blood

Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, announced Allergan plc (NYSE: AGN) has exercised its option to acquire drug candidate AGN-241751, an oral small-molecule N-methyl-D-aspartate (NMDA) receptor modulator. Aptinyx discovered AGN-241751 utilizing its proprietary chemistry platform and the compound was selected for further development by Allergan under its ongoing research collaboration with Aptinyx.

Allergan was granted option rights to a limited number of small molecules from the Aptinyx discovery platform under a research collaboration initiated in conjunction with its 2015 acquisition of Naurex, the predecessor company from which Aptinyx and its platform were spun out. Through that transaction, Allergan also acquired rapastinel, an intravenously administered NMDA receptor modulating tetrapeptide. Subsequently, rapastinel received Breakthrough Therapy designation from the U.S. Food and Drug Administration and Allergan is currently evaluating the compound in Phase 3 studies in major depressive disorder (MDD).

“Through our productive research collaboration with Aptinyx and parallel development of rapastinel, we have gained important insights into NMDA receptor modulation as a potential therapeutic approach for depression,” said C. David Nicholson, Ph.D., chief R&D officer at Allergan. “We plan to advance AGN-241751 for the treatment of MDD and believe its pharmacological profile will enable it to become an oral complement to rapastinel, further bolstering our pipeline of therapeutics addressing areas of significant unmet medical need.”

“Our research collaboration with Allergan has been fruitful for both parties and we are pleased our collaboration partner has elected to option and continue clinical development of AGN241751 to augment its CNS portfolio,” said Norbert Riedel, Ph.D., president and chief executive officer of Aptinyx. “The exercise of this option underscores the therapeutic potential of molecules generated from our discovery platform, which modulate NMDA receptors in a novel and differentiated way and may significantly improve the lives of patients suffering from various neurologic disorders.”

Aptinyx and Allergan entered into their research collaboration to discover and characterize novel small-molecule NMDA receptor modulators using Aptinyx’s proprietary chemistry platform. Under the collaboration, Allergan funds a portion of the collaboration costs and receives options to acquire a defined number of compounds for development and commercialization within a limited field of indications. None of the molecules Aptinyx has advanced into clinical development are subject to any Allergan option right.

 

About Pharmascroll:

Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease indications prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide analytical and logical answers to the key business questions of the pharmaceutical and medical insights teams and to make better informed business decisions with the detailed relevant information available.

To read more news about Depression, visit https://pharmascroll.com/news-category/depression/

 

News Source: Aptinyx website

Image source: https://www.ramsayhealth.co.uk/about/latest-news/depression-blood-test